BioTechnique, a specialty drug aseptic fill-finish contract manufacturing organization, will launch a second phase of manufacturing in partnership with a major, international not-for-profit organization, the company announced recently.

“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” BioTechnique CEO John Clapham said in a statement. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”

According to a release, BioTechnique will manufacture a commercially available vaccine product in a new, shelf-stable dosage form.

The first phase of manufacturing happened in late 2015, and the vaccine product went into the clinic early 2016.